Glenmark gets FDA's blessing for generic Aubagio

Press enter to search
Close search
Open Menu

Glenmark gets FDA's blessing for generic Aubagio

By Sandra Levy - 11/16/2018
Glenmark Pharmaceuticals has received the Food and Drug Administration's approval for teriflunomide tablets in 7-mg and 14-mg dosage strengths.

The product is a generic version of Sanofi-Aventis’ Aubagio tablets 7 mg and 14 mg. It is used to treat relapsing forms of multiple sclerosis.

Aubagio tablets 7 mg and 14 mg had a market value of approximately $1.6 billion for the 12-month period ending September 2018, according to IQVIA.

RELATED TOPICS